J&J, Pharmacyclics leukemia drug effective long term: study

[riky]

J&J, Pharmacyclics leukemia drug effective long term: study

A closely watched leukemia drug developed by Johnson & Johnson and Pharmacyclics Inc maintained its effectiveness in keeping the disease at bay for most patients, according to long-term follow-up data from a midstage study being presented at a major medical meeting. The oral drug, ibrutinib, last month won U.S. approval to treat a rare and aggressive form of non-Hodgkin lymphoma known as mantle cell lymphoma. It is awaiting a Food and Drug Administration decision on treating chronic lymphocytic leukemia (CLL), a slowly progressing form of blood cancer that primarily affects people aged 65 and older. Some industry analysts had expected the CLL approval to come at the same time as the lymphoma decision.

Source: You are not allowed to view links. Register or Login